A two-month study involving patients with MDD found that fluvoxamine alleviated depressive symptoms and lowered interleukin-6 (IL-6) levels, with these effects partially mediated by sigma receptor activity (ClinicalTrials.gov Identifier: NCT04160377) (Li X. et al., 2023). Here, IL6 is linked to major depressive disorder.